Novartis To Launch Nycomed's PPI Pantoloc Control In 14 European Countries
This article was originally published in The Tan Sheet
Executive Summary
Novartis will launch the OTC proton pump inhibitor Pantoloc Control (pantoprazole 20 mg) in 14 European countries in the second quarter of 2010 under a co-marketing agreement with the product's originator Nycomed
You may also be interested in...
Takeda Gains Access To European OTC Market With $13.7B Nycomed Buy
Japanese pharma giant Takeda Pharmaceuticals Co. Ltd. gains access to the European OTC market with its $13.7 billion purchase of Swiss firm Nycomed AS.
Takeda Gains Access To European OTC Market With $13.7B Nycomed Buy
Japanese pharma giant Takeda Pharmaceuticals Co. Ltd. gains access to the European OTC market with its $13.7 billion purchase of Swiss firm Nycomed AS.
Takeda Gains Access To European OTC Market With $13.7B Nycomed Buy
Japanese pharma giant Takeda Pharmaceuticals Co. Ltd. gains access to the European OTC market with its $13.7 billion purchase of Swiss firm Nycomed AS.